Search
for

    Did you mean Bitemporal Recession?
    GlossaryTemporal Hair Loss (Bitemporal Recession)

    gradual hair thinning at the temples

    Temporal hair loss, also known as temporal alopecia or thinning hair at the temples, refers to the gradual loss of hair in the temple regions of the scalp. This condition can be caused by various factors, including genetics, hormonal changes, stress, or certain medical conditions. It is often an early sign of androgenetic alopecia (male or female pattern baldness) and can be addressed through treatments like topical minoxidil, oral medications, or lifestyle changes.

    Related Terms

    Learn

    0 / 0 results
    — no results

    Research

    5 / 559 results

    Community Join

    4 / 4 results
      If You Have DUPA, PLEASE READ THIS: Everyone Should Be Scalp Biopsied

      community If You Have DUPA, PLEASE READ THIS: Everyone Should Be Scalp Biopsied

      in Research  830 upvotes 1 year ago
      Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.
      Should i be worried dut 6 months

      community Should i be worried dut 6 months

      in General  122 upvotes 5 days ago
      The user has been using finasteride and minoxidil, then switched to dutasteride and minoxidil for six months without significant results, noticing thinning after increasing creatine dosage. They plan to consult a dermatologist to explore potential causes beyond androgenetic alopecia.

      community PP405 2a study was a safety study. Some rational explaining.

      in Research/Science  22 upvotes 4 months ago
      The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.